Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Morphic Holding Inc chart...

About the Company

oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Exchange

NASDAQ

$19M

Total Revenue

117

Employees

$2B

Market Capitalization

-10.03

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MORF News

Morphic Holding: Strong Financials and Promising Clinical Trials Reinforce Buy Rating

10d ago, source:

Canaccord Genuity analyst Edward Nash maintained a Buy rating on Morphic Holding (MORF – Research Report) yesterday and set a price ...

Morphic Holding Inc MORF

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?

21d ago, source: Hosted on MSN

Morphic Holding, Inc. (MORF) closed the last trading session at $35.30, gaining 16.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Morphic Holding’s Buy Rating Affirmed on Strong Clinical and Financial Prospects

25d ago, source: Business Insider

Morphic Holding (MORF) Company Description: Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics.

MORF Jul 2024 17.500 put

3d ago, source: Yahoo Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 56.2% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is ...

Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet

1mon ago, source: Yahoo Finance

Morphic Holding, Inc. (MORF) closed the last trading session at $36.82, gaining 27% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...

Morphic Holding Stock (NASDAQ:MORF), Quotes and News Summary

21d ago, source: Benzinga.com

Since Friday, Morphic Therapeutic (NASDAQ ... Moving In Monday's Mid-Day Session Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced ...

New Strong Buy Stocks for February 14th

1mon ago, source: Hosted on MSN

Lumen Technologies, Inc. price-consensus-chart | Lumen Technologies, Inc. Quote Morphic Holding, Inc. MORF: This biopharmaceutical company has seen the Zacks Consensus Estimate for its current ...

Morphic Holding Inc MORF

1mon ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Morphic Holding Inc (MORF)

6d ago, source: Investing

On Wednesday, Jefferies showed increased confidence in Morphic Therapeutic (NASDAQ:MORF) by raising the company's price target from $45.00 to $60.00. The firm maintained a Buy ...

Morphic Holding Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...